Format

Send to

Choose Destination
Semin Oncol. 2015 Jun;42(3):436-47. doi: 10.1053/j.seminoncol.2015.02.012. Epub 2015 Feb 14.

Immune checkpoint blockade and interferon-α in melanoma.

Author information

1
University of Pittsburgh Medical Center, Pittsburgh, PA.
2
University of Pittsburgh Medical Center, Pittsburgh, PA; University of Pittsburgh Cancer Institute, Pittsburgh, PA.
3
University of Pittsburgh Medical Center, Pittsburgh, PA; University of Pittsburgh Cancer Institute, Pittsburgh, PA. Electronic address: tarhiniaa@upmc.edu.

Abstract

The quality of the host immune response in patients with advanced melanoma is compromised with a bias towards Th2-type polarization and a tumor microenvironment that facilitates disease progression. Overcoming tumor-induced immune suppression through strategies that build upon the immunomodulatory qualities and clinical activity of interferon-α as demonstrated in the melanoma adjuvant setting is a major clinical need. The recent advances in the field of immune checkpoint modulation and the unprecedented clinical activity in advanced melanoma opens the door on novel combinations that may overcome tumor tolerogenic mechanisms that are known to suppress the potent anti-tumor impact of interferon (IFN)-α. Promising preliminary data suggest that such combinations may move the clinical management of advanced melanoma into the next level, beyond what is currently seen with immune checkpoint blockers alone.

PMID:
25965362
PMCID:
PMC4429252
DOI:
10.1053/j.seminoncol.2015.02.012
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Elsevier Science Icon for PubMed Central
Loading ...
Support Center